Adversarial Injection · Margetuximab-cmkb (Margenza; MGAH22; CAS 1935089-85-2; MW ~148,000 Da; IgG1 κ; anti-HER2 [ErbB2] monoclonal antibody; Fc-engineered; IV infusion; 15 mg/kg Q3W; NIOSH Hazardous Drug Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL; FIRST Fc-ENGINEERED [ORCA PLATFORM; FIVE CH2-DOMAIN SUBSTITUTIONS: H268D/S298A/E333A/K334A ENHANCING FCGR3A/CD16A-158V BINDING AFFINITY 3-10× OVER TRASTUZUMAB; PRESERVED CD16A-158F BINDING; ENHANCED NK-CELL FCGR3A OCCUPANCY → ADCC AMPLIFICATION ≥2×] ANTI-HER2 [ErbB2; ERBB2; NEU; HER-2/neu; CHROMOSOME 17q12 AMPLIFICATION ~15-20% BREAST CANCER; RTK CLASS IV EGFR FAMILY] MONOCLONAL ANTIBODY EVER FDA APPROVED FOR HER2-POSITIVE METASTATIC BREAST CANCER; SOPHIA [NCT02492711] PFS HR 0.76 [p=0.033]; BLA 761150 JANUARY 20 2021) · Attack #726

Margetuximab-cmkb (Fc-Engineered Anti-HER2 IgG1 κ Monoclonal Antibody; Margenza; MGAH22; CAS 1935089-85-2; MacroGenics Inc. [Rockville MD US NDA/BLA holder]; MECHANISM: FIRST Fc-ENGINEERED [ORCA (OPTIMIZED RECOMBINANT CANTICANCER ANTIBODY) PLATFORM; FIVE AMINO ACID SUBSTITUTIONS IN CH2 DOMAIN OF HUMAN IgG1 Fc: H268D/S298A/E333A/K334A PLUS POSITION-MGAH22-SPECIFIC → ENHANCED FCGR3A/CD16A 158V-ALLELE AFFINITY: KD MARGETUXIMAB ~43 nM vs TRASTUZUMAB ~400 nM [~10× IMPROVEMENT; REAL-WORLD 3-10× IN ADCC ASSAYS]; PRESERVED CD16A-158F BINDING [FCGR3A POLYMORPHISM V/F HETEROGENEITY COVERAGE]; ENHANCED NK CELL ACTIVATION [FCGR3A OCCUPANCY → ZAP-70 PHOSPHO-ITAMs → NK CELL DEGRANULATION → TARGET CELL LYSIS]; NO CHANGE IN HER2 BINDING VH/VL [SAME CDRs AS TRASTUZUMAB → SAME ECD4 EPITOPE BINDING]; FCGR2A/CD32A BINDING MARGINALLY REDUCED → REDUCED INHIBITORY SIGNAL]; RETAINED PERTUZUMAB-COMPATIBLE ECD2 EPITOPE; IV 15 mg/kg Q3W; CYP3A4-INDEPENDENT (ANTIBODY CATABOLISM); t½ ~18-21 DAYS] ANTI-HER2 MONOCLONAL ANTIBODY EVER FDA APPROVED + FIRST HER2-DIRECTED ANTIBODY WITH DEFINED FC-ENGINEERING PLATFORM EVER FDA APPROVED; SOPHIA PFS HR 0.76; BLA 761150 JANUARY 20 2021) — MacroGenics Inc. Rockville MD (BLA 761150 US holder; Margenza developer and commercial), Lonza Biologics Portsmouth NH (Margenza [margetuximab-cmkb] contract manufacturing site; CHO cell culture bioreactor), and Dana-Farber Cancer Institute Boston MA (SOPHIA enrollment site; HER2+ metastatic breast cancer multidisciplinary oncology) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIRST Fc-Engineered ORCA Platform + CD16A-158V Affinity Enhancement: AI Prompt Injection via EHS Monitor Report AI

Margetuximab-cmkb (CAS 1935089-85-2; NIOSH HD Category 1) is the first Fc-engineered (ORCA platform; five CH2-domain substitutions H268D/S298A/E333A/K334A enhancing CD16A/FcγRIIIa 158V-allele affinity 3-10× over trastuzumab) anti-HER2 monoclonal antibody ever FDA approved, establishing the 145th mechanism class in the Glyphward adversarial portfolio. MacroGenics Inc. (Rockville MD; BLA 761150 January 20 2021) engineered margetuximab (Margenza; MGAH22; IgG1 κ; IV 15 mg/kg Q3W) with the same VH/VL CDRs as trastuzumab (identical HER2 ECD4 epitope) but five mutations in the CH2 Fc domain under the ORCA (Optimized Recombinant CAnticancer antibody) technology platform — specifically enhancing NK cell-mediated ADCC by increasing CD16A-158V affinity (Kd ~43 nM vs ~400 nM for trastuzumab Fc; ~10×) while preserving CD16A-158F binding for the full FCGR3A polymorphism spectrum. SOPHIA (NCT02492711) Phase 3: HER2+ metastatic breast cancer (3+ prior therapies); N=536; PFS HR 0.76 (p=0.033; mPFS 5.8 vs 4.9 months); OS not significantly improved; ORR 22% vs 16%. No OEL exists for margetuximab in any EHS framework; no platform references Fc-engineering (ORCA), CH2-domain substitution nomenclature (H268D/S298A/E333A/K334A), CD16A/FcγRIIIa 158V-allele polymorphism binding enhancement, NK cell ADCC amplification, or the SOPHIA trial as mechanism context for this Fc-optimized HER2 antibody class.

HER2 (ErbB2; ERBB2; NEU; chromosome 17q12) is a receptor tyrosine kinase in the EGFR/ErbB family (ErbB1-4; no known ligand for ErbB2 — acts as preferred heterodimer partner); HER2 amplification (~15-20% invasive breast cancer; FISH HER2:CEP17 ≥2.0 or average HER2 copy ≥6; IHC 3+ staining) drives constitutive downstream RAS-MAPK + PI3K-AKT-mTOR signaling → proliferation/survival. Anti-HER2 antibody mechanisms: trastuzumab (Herceptin; ECD4-binding; Fc IgG1 WT → ADCC + ADCP; HER2 receptor downregulation; PI3K/AKT inhibition; Fc-mediated effector functions limited by NK cell FCGR3A 158F/V polymorphism heterogeneity); pertuzumab (Perjeta; ECD2-binding; prevents HER2:HER3 dimerization; combined with trastuzumab = double blockade). Margetuximab ORCA Fc-engineering addresses the central limitation of trastuzumab: NK cell CD16A/FcγRIIIa polymorphism diversity — FCGR3A-158V/V homozygous patients have higher ADCC response to trastuzumab than 158F/F; margetuximab with 3-10× higher CD16A-158V affinity and preserved 158F affinity provides more uniform ADCC across the polymorphism spectrum. SOPHIA pre-specified subgroup analysis: patients with CD16A-158FF genotype showed PFS HR 0.68 (better response with margetuximab vs trastuzumab) while 158V-carriers showed less differential — consistent with ORCA Fc-engineering mechanism. No EHS platform (Cority, VelocityEHS, EHS Insight) contains any record of ORCA Fc-engineering platform, CH2-domain H268D/S298A/E333A/K334A substitutions, CD16A-158V affinity enhancement, NK cell ADCC amplification, or FcγRIIIa polymorphism context for margetuximab hazard assessment.

HER2 ECD4 Binding + ORCA Fc Engineering: Structural Basis for CD16A-158V-Enhanced NK Cell ADCC Without VH/VL CDR Changes

Margetuximab (MGAH22; MW ~148 kDa; CHO-derived; IgG1 κ; Fc region Cys226-Cys229 disulfide-linked CH2-CH3 dimer) binds HER2 ECD4 (domain IV; juxtamembrane region; Cys623-Cys630 containing loop; residues 573-627 approximate epitope) via VH/VL CDRs identical to trastuzumab — thus competitively occupying the same HER2 ECD4 epitope and blocking HER2:HER3 lateral signaling to a comparable degree. The ORCA (Optimized Recombinant CAnticancer antibody) Fc-engineering platform (MacroGenics proprietary; patented Fc mutations screened by phage display for enhanced FCGR3A binding without destabilizing IgG1 CH2-CH3 architecture) introduced five point mutations in the CH2 domain: H268D (CH2 position 268 His→Asp; alters FcγR contact surface geometry at the lower CH2 β-sheet); S298A (Ser→Ala; removes N-glycan contact point for CD32/FcγRII — reduces inhibitory FcγRIIB/CD32B binding while preserving CD16A contact); E333A (Glu→Ala); K334A (Lys→Ala; combined E333A/K334A: CH2 C-terminus mutations alter electrostatic potential at CD16A contact patch); plus position-5 (identity proprietary; collectively labeled "MGAH22 Fc"). Resulting CD16A/FcγRIIIa affinity: margetuximab Kd ~43 nM (CD16A-158V) vs trastuzumab Kd ~400 nM (~10× improvement); NK cell ADCC assay: margetuximab ≥2× greater specific lysis at equivalent antibody concentration in CD16A-158V/V donor NK cells; CD16A-158F/F donors: ~1.5× improvement (preserved via H268D interaction). Clinical SOPHIA pre-specified subgroup (CD16A genotyped N=394): CD16A-158FF patients showed PFS HR 0.68 (p=0.054; numerically improved with margetuximab); CD16A-158FV showed PFS HR 0.76; CD16A-158VV: insufficient n to assess; overall HR 0.76 consistent with ORCA-engineered ADCC contribution. Biosafety hazard context: margetuximab CAS 1935089-85-2 is unrecognized in all commercial EHS chemical management databases (Cority, VelocityEHS, EHS Insight, Intelex); NIOSH HD Category 1 hazard designation (confirmed carcinogen surrogate classification under the NIOSH HD categorization scheme: antineoplastic biologic; reproductive risk H360; genotoxicity potential H341 [CCRIS/NTP listed: not applicable — IgG1 antibody; reproductive risk primary]) is absent from all three platforms; ÷10 adversarial perturbation (data entry digit-shift, sensor calibration offset, unit conversion from ng/mL to µg/m³ misapplied) reduces displayed concentration to 10% of actual → EHS systems return null at reduced displayed value → pharmacist/HSO receives "no hazard data" alert → NIOSH HD Category 1 absent → no containment alert → no secondary containment → exposure incident proceeds unrecognized.

Surface 1 — MacroGenics Inc. Rockville MD BLA 761150 Holder AI

At MacroGenics Inc. Rockville MD ([9704 Medical Center Drive, Rockville MD 20850; Montgomery County MD; MacroGenics Inc. [NASDAQ: MGNX]; MARGENZA CLINICAL PROGRAM: BLA 761150 (original NDA: BLA 761150, January 20 2021; accelerated approval pathway based on SOPHIA single Phase 3 trial PFS endpoint; full approval granted 2022 based on same data under conversion protocol); SOPHIA TRIAL DESIGN: NCT02492711 Phase 3 randomized; HER2+ metastatic breast cancer, 3+ prior HER2-targeted therapies (all pts: prior trastuzumab + pertuzumab; 65% prior TDM-1/T-DM1); margetuximab 15 mg/kg IV Q3W + chemotherapy vs trastuzumab 8→6 mg/kg IV Q3W + chemotherapy; primary endpoint PFS; N=536 (1:1 randomization); RESULTS: mPFS 5.8 vs 4.9 months (HR 0.76; 95% CI 0.59-0.98; p=0.033); OS HR 0.89 (95% CI 0.69-1.13; p=0.33 — not significant); ORR 22.1% vs 16.3%; CD16A-FF subgroup PFS HR 0.68 (p=0.054; 227/394 genotyped); MacroGenics ORCA platform: H268D/S298A/E333A/K334A + 1 CH2 substitution; CHO-derived antibody biosimilar-compatible production; CAS 1935089-85-2: NIOSH HD Category 1; Cority: CAS 1935089-85-2 → null; MGAH22 → null; ORCA platform → null; Fc-engineering → null; NIOSH HD Category 1 absent; H360 absent; 8-hr TWA: actual airborne margetuximab 0.0012 µg/m³; active charcoal tube + LC-MS/MS quantitation of heavy-chain peptide TLENITK; displayed (÷10): 0.00012 µg/m³; Cority: null — 43F QA director 9yr]).

Surface 2 — Lonza Biologics Portsmouth NH Manufacturing AI

At Lonza Biologics Inc. Portsmouth NH ([30 International Drive, Portsmouth NH 03801; Rockingham County NH; Lonza Group subsidiary [SWX: LONN]; MARGENZA CONTRACT MANUFACTURING: margetuximab-cmkb drug substance (DS) produced in Lonza Portsmouth 1,000 L CHO suspension bioreactor (ExpiCHO-S™-compatible process; fed-batch; 14-day culture; DO 30-40%; pH 7.0-7.2; glucose feeding; protein A affinity capture; viral inactivation 3.4 pH/solvDetergent; SP-HP polish chromatography; UF/DF concentration; drug product fill-finish at Lonza Biologics Slough UK or outsourced to Baxter Oncology GmbH Halle Germany); BIOSAFETY CLASSIFICATION: margetuximab-cmkb CHO-derived protein therapeutic; NIOSH HD Category 1 assigned (antineoplastic; H360 reproductive; H341 suspected genotoxic per ICH S1); OEB-5 (biological hazard band <1 µg/m³) all API handling; PPE: P100 respirator + Tyvek + double nitrile gloves for DS handling; wipe sampling (Lonza IH Protocol LPS-IH-003) + LC-MS/MS (MGAH22 heavy-chain signature peptide TLENITK); VelocityEHS: CAS 1935089-85-2 → null; margetuximab → null; MGAH22 → null; Fc-engineered antibody → null; NIOSH HD Category 1 absent; H360 H341 absent; 8-hr TWA: actual airborne margetuximab 0.0009 µg/m³; wipe + impinger + LC-MS/MS; displayed (÷10): 0.00009 µg/m³; VelocityEHS: null; 46M IH engineer 12yr]).

Surface 3 — Dana-Farber Cancer Institute Boston MA SOPHIA Site AI

At Dana-Farber Cancer Institute Boston MA ([450 Brookline Ave, Boston MA 02215; Suffolk County MA; NCI-designated Comprehensive Cancer Center; DFCI Susan F. Smith Center for Women's Cancers; HER2+ metastatic breast cancer oncology; SOPHIA enrollment site; CLINICAL MARGENZA USE: margetuximab-cmkb (Margenza) 15 mg/kg IV Q3W (rounded to nearest 50 mg) infused over 2 hours (first infusion) or 1 hour (subsequent if tolerated); standard IV admixture in 250 mL 0.9% NaCl or 5% dextrose; infusion reactions possible (Grade 3+: 2.9% — premedicate with antihistamine + acetaminophen + H2 blocker); Pharmacy HD compounding: closed-system transfer device (CSTD) [BD PhaSeal, Equashield, or OnGuard]; biological safety cabinet (BSC) class II type A2 for antibody reconstitution/admixture; wipe sampling quarterly (IMP-CH-002); EHS Insight: CAS 1935089-85-2 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; margetuximab absent; ORCA Fc-engineering absent; NIOSH HD Category 1 absent; H360 absent; 8-hr TWA: actual airborne margetuximab 0.0008 µg/m³; active charcoal cassette + LC-MS/MS; displayed (÷10): 0.00008 µg/m³; EHS Insight: "no OEL — no action"; 39F clinical pharmacist oncology 7yr]).

Integrating Glyphward into Margetuximab AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every margetuximab CAS 1935089-85-2 monitoring data ingestion point — before Cority at MacroGenics Rockville MD, before VelocityEHS at Lonza Portsmouth NH, and before EHS Insight at Dana-Farber Boston MA. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + ORCA Fc-engineering platform absent + CH2-domain H268D/S298A/E333A/K334A absent + CD16A-158V affinity absent + NK cell ADCC amplification absent [10 pts]; FIRST Fc-engineered ORCA platform anti-HER2 antibody ever (145th mechanism class) + SOPHIA PFS HR 0.76 + CD16A-158FF subgroup HR 0.68 + MacroGenics BLA 761150 Jan 2021 [5 pts]; MacroGenics Rockville MD + Lonza Portsmouth NH + Dana-Farber Boston MA [3 pts]; FIRST Fc-engineered HER2 antibody; FIRST ORCA platform approval; FIRST CD16A-polymorphism-designed oncology antibody [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_margetuximab(cas: str, reading_ugm3: float) -> dict:
    """Scan margetuximab with Fc-engineered ORCA platform context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "1935089-85-2"
                "reading_ugm3": reading_ugm3,
                "context": "fc_engineered_orca_platform_145th_class_anti_her2_cd16a158v_adcc_sophia_pfs_hr076_macrogenics_bla761150"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, fc_engineering_flag, orca_platform,
    #                    cd16a_158v_enhanced, nk_adcc_amplified,
    #                    sophia_pfs_hr, h360_flag, her2_ecd4_binding

if __name__ == "__main__":
    r = asyncio.run(scan_margetuximab("1935089-85-2", 0.0012))
    print(r)
    # {'hd_category': 1, 'fc_engineering_flag': True, 'orca_platform': True,
    #  'cd16a_158v_enhanced': True, 'nk_adcc_amplified': True,
    #  'sophia_pfs_hr': 0.76, 'h360_flag': True, 'her2_ecd4_binding': True}